Lake Street Advisors Group LLC grew its stake in Novartis AG (NYSE:NVS – Free Report) by 127.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 17,119 shares of the company’s stock after buying an additional 9,591 shares during the period. Lake Street Advisors Group LLC’s holdings in Novartis were worth $1,969,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Founders Financial Securities LLC grew its position in Novartis by 3.4% in the 2nd quarter. Founders Financial Securities LLC now owns 2,832 shares of the company’s stock worth $301,000 after purchasing an additional 94 shares during the last quarter. Steigerwald Gordon & Koch Inc. grew its position in Novartis by 4.8% in the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after purchasing an additional 95 shares during the last quarter. NBC Securities Inc. grew its position in Novartis by 0.9% in the 2nd quarter. NBC Securities Inc. now owns 10,492 shares of the company’s stock worth $1,116,000 after purchasing an additional 97 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Novartis by 5.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,013 shares of the company’s stock worth $196,000 after purchasing an additional 98 shares during the last quarter. Finally, Portside Wealth Group LLC grew its position in Novartis by 3.4% in the 2nd quarter. Portside Wealth Group LLC now owns 3,000 shares of the company’s stock worth $319,000 after purchasing an additional 99 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.
Novartis Stock Performance
NYSE NVS traded up $0.80 on Friday, hitting $113.93. 156,760 shares of the stock were exchanged, compared to its average volume of 1,328,768. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. The business’s fifty day moving average is $116.44 and its 200 day moving average is $108.39. Novartis AG has a 52 week low of $92.19 and a 52 week high of $120.92. The company has a market capitalization of $232.87 billion, a PE ratio of 15.37, a P/E/G ratio of 1.66 and a beta of 0.57.
Analyst Ratings Changes
Read Our Latest Report on Novartis
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Read More
- Five stocks we like better than Novartis
- What is the Nasdaq? Complete Overview with History
- Texas Roadhouse Stock Steering for New Highs This Year
- Stock Sentiment Analysis: How it Works
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.